Optimizing chemotherapy-free survival for the ER/HER2-positive metastatic breast cancer patient

Clinical Cancer Research

Volumn 17, Issue 17, 2011, Pages 5559-5561

  Glück, Stefan ^a   Arteaga, Carlos L ^b   Osborne, C Kent ^c  

^a UNIVERSITY OF MIAMI   (United States)

^b VANDERBILT INGRAM CANCER CENTER   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; BEVACIZUMAB; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; EXEMESTANE; FULVESTRANT; GEFITINIB; LAPATINIB; LETROZOLE; MAMMALIAN TARGET OF RAPAMYCIN; PAZOPANIB; PHOSPHATIDYLINOSITOL 3 KINASE; PLACEBO; SCATTER FACTOR; SOMATOMEDIN RECEPTOR; TAMOXIFEN; TRASTUZUMAB; VASCULOTROPIN;

ARTICLE; BREAST CANCER; CANCER PATIENT; CHEMOTHERAPY FREE SURVIVAL; DRUG TARGETING; HUMAN; METASTASIS; PRIORITY JOURNAL; SURVIVAL;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CLINICAL TRIALS AS TOPIC; FEMALE; HUMANS; MOLECULAR TARGETED THERAPY; RECEPTOR CROSS-TALK; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; SIGNAL TRANSDUCTION; TAMOXIFEN;

EID: 80052516349     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-10-2051     Document Type: Article

References (28)

1. American Cancer Society: Breast cancer facts and figures 2009. Atlanta, GA, American Cancer Society. Inc , 2009.
2. Chia SK, Speers CH, D'yachkova Y, Kang A, Malfair-Taylor S, Barnett J, et al. The impact of new chemotherapeutic and hormone agents on survival in a population-based cohort of women with metastatic breast cancer. Cancer 2007;100:973-9.
3. Buzdar AU. Role of biologic therapy and chemotherapy in hormone receptor-and HER2-positive breast cancer. Ann Oncol 2009;20: 993-9.
4. Johnston S, Pippen J, Pivot X, Lichinitser M, Sadeghi S, Dieras V, et al. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. J Clin Oncol 2009;27:5538-46.
5. Zahnow CA. ErbB receptors and their ligands in the breast. Expert Rev Mol Med 2006;8:1-21.
6. Zhang H, Berezov A, Wang Q, Zhang G, Drebin J, Murali R, et al. ErbB receptors: from oncogenes to targeted cancer therapies. J Clin Invest 2007;117:2051-58.
7. Badache A, Goncalves A. The ErbB2 signaling network as a target for breast cancer therapy. J Mammary Gland Biol Neoplasia 2006;11: 13-25.
8. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989;244:707-12.
9. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, et al. for the Herceptin Adjuvant (HERA) Trial Study Team: Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005;353:1659-72.
10. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE, Davidson NE, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005;353:1673-84.
11. Marcom PK, Issacs C, Harris L, Bryant M, Kommareddy A, Tao Y, et al. A phase II trial of letrozole and trastuzumab for ER and/or PgR and HER2 positive metastatic breast cancer: final results. J Clin Oncol 2005;23:16s suppl; Abstract no. 596.
12. Arpino G, Weichmann L, Osborne CK, Schiff R. Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: molecular mechanism and clinical implications for endocrine therapy resistance. Endocr Rev 2008;29:217-33.
13. Massarweh S, Osborne CK, Creighton CJ, Qin L, Tsimelzon A, Huang S, et al. Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function. Cancer Res 2008;68:826-33.
14. Lipton A, Leitzel K, Ali SM, Demers L, Harvey HA, Chaudri-Ross HA, et al. Serum HER-2/neu conversion to positive at the time of disease progression in patients with breast carcinoma on hormone therapy. Cancer 2005;104:257-63.
15. Mackey JR, Kaufman B, Clemens M, et al. Trastuzumab prolongs progression-free survival in hormone-dependent and HER2-positive metastatic breast cancer. Breast Cancer Res Treat 2006;100:S5. Abstract no. 3.
16. Osborne K, Neven P, Dirix L, Mackey J, Robert J, Underhill C, et al. Randomized Phase II Study of gefitinib (IRESSA) or placebo in combination with tamoxifen in patients with hormone receptor positive metastatic breast cancer. Presented at 30th Annual San Antonio Breast Cancer Symposium, San Antonio, TX, December 14 2007. Abstract no. 2067.
17. Cristofanilli M, Valero V, Mangalik A, Royce M, Rabinowitz I, Arena FP, et al. A phase II multicenter, double-blind, randomized trial to compare anastrozole plus gefinitib with anastrozole plus placebo in postmenopausal women with hormone receptor-positive (HR+) metastatic breast cancer (MBC). J Clin Oncol 2008;26:15s. Suppl; Abstract no. 1012.
18. Carlson RW, O'Neill A, Vidaurre T, Gomez HL, Badve S, Eastern Cooperative Oncology Group, et al. Randomized phase II trial of gefitinib plus anastrozole or fulvestrant in postmenopausal, metastatic breast cancer. J Clin Oncol 2009;27:15s. Suppl; Abstract no. 1013.
19. Cristofanilli M, Schiff R, Valero V, Iacona R, Yu J, Speake G, et al. Exploratory subset analysis according to prior endocrine treatment of two randomized phase II trials comparing gefitinib (G) with placebo (P) in combination with tamoxifen (T) or anastrozole (A) in hormone receptor-positive (HR+) metastatic breast cancer (MBC). J Clin Oncol 2009;27:15s. Suppl; Abstract no. 1014.
20. ClinicalTrials.gov: Fulvestrant and/or trastuzumab as first-line therapy in treating postmenopausal women with stage IV breast cancer [cited 2011 Jun 17]. Available from: http://www. clinicaltrials.gov/ct2/show/NCT00138125.
21. ClinicalTrials.gov: Bevacizumab given with either anastrozole or fulvestrant with trastuzumab for postmenopausal metastatic breast cancer [cited 2011 Jun 17]. Available from: http://www. clinicaltrials.gov/ct2/show/ NCT00405938.
22. ClinicalTrials.gov: Treatment of HER2-positive metastatic breast cancer with herceptin and bevacizumab (antibodies against HER2 and VEGF) [cited 2011 Jun 17]. Available from: http:// www.clinicaltrials.gov/ct2/show/NCT00095706.
23. Slamon D, Gomez HL, Kabbinavar FF, Amit O, Richie M, Pandite L, et al. Randomized study of pazopanib + lapatinib vs. lapatinib alone in patients with HER2-positive advanced or metastatic breast cancer. J Clin Oncol 2008;26:15s. Suppl; Abstract no. 1016.
24. Leary AF, Drury S, Detre S, Pancholi S, Lykkesfeldt AE, Martin LA, et al. Lapatinib restores hormone sensitivity with differential effects on estrogen receptor signaling in cell models of human epidermal growth factor receptor 2-negative breast cancer with acquired endocrine resistance. Clin Cancer Res 2010;16:1486-97.
25. Mayer IA, Arteaga CL. Does lapatinib work against HER2-negative breast cancers? Clin Cancer Res 2010;16:1355-7.
26. Gutierrez MC, Detre S, Johnston S, Mohsin SK, Shou J, Allred DC, et al. Molecular changes in tamoxifen-resistant breast cancer: relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase. J Clin Oncol 2005;23:2469-76.
27. Cardoso F, Castiglione M. Locally recurrent or metastatic breast cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2009;20:Suppl 4:15-8.
28. Goldhirsch A, Ingle JN, Gelber RD, Coates AS, Thürlimann B, Senn HJ, et al. Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of earlybreast cancer 2009. Ann Oncol 2009;20:1319-29.